Thincal

Orlistat

Method of action: Antiobesity Preparations, Excl. Diet Products, Dietary Fat Absorption Inhibitor, Inhibitory Gastrointestinal Lipases, Lipid Modifying Agents

Treatment option: Dyslipidemia, Obesity, Weight Loss, Diabetes Mellitus

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Thincal

Quick Facts

Property	Description
Active ingredient	Orlistat
Form	Oral formulation, typically a capsule
Pharmacological class	Gastrointestinal Lipase Inhibitor / Anti-obesity Agent
Common use	Adjuvant therapy for weight loss and weight maintenance
Origin	Synthetic compound

What is Thincal and Its Purpose?

Thincal is a brand name for a pharmaceutical preparation containing the active ingredient Orlistat, which is a clinically recognized agent used to support efforts in weight management. It is explicitly classified as an anti-obesity agent belonging to the pharmacological class of gastrointestinal lipase inhibitors. This classification corresponds with its mechanism of action. Thincal is designated as a prescription-only (Rx) medicine, typically intended for use by adults and adolescents who require support in managing obesity. The medicine's general therapeutic purpose is to help patients achieve a necessary caloric deficit by reducing the amount of fat-derived energy absorbed from consumed food. Orlistat is utilized alongside dietary intervention to support weight loss, serving as a functional adjunct therapy.

Composition, Classification, and Origin of Orlistat

The active substance, Orlistat, is a synthetic compound that was chemically synthesized as a saturated derivative of lipstatin, a potent natural inhibitor. Thincal is provided as an oral formulation, typically packaged as a capsule, and is consistently a single-ingredient product. This defined form ensures reliable delivery of the compound via the oral route of administration. The unique property of Orlistat, which differentiates it from other weight management compounds, is that its therapeutic effect is non-systemic, meaning its influence is localized entirely to the gut lumen. This characteristic indicates that the primary focus of the medicine is the direct blockage of fat digestion within the intestine, rather than acting on central physiological processes.

What side effects are possible with Thincal?

Possible side effects and safety information

The safety profile of Thincal (Orlistat) is primarily characterized by adverse reactions that are localized to the gastrointestinal system, which aligns with its non-systemic mechanism of action. Official regulatory documents classify these effects by frequency and system-organ class.

Frequency and Adverse Reactions

Very Common Reactions (occurring in ge 1 in 10 patients) typically involve the digestive tract and include oily spotting, flatulence with discharge, fecal urgency, fatty/oily stools, and an increase in defecation. Headache and upper respiratory tract infection are also officially classified in this frequency tier. Common Reactions (occurring in ge 1 in 100 to < 1 in 10 patients) include anxiety, nausea, rectal pain, soft stools, and menstrual irregularity.

Uncommon effects (ge 1 in 1,000 to < 1 in 100 patients) include certain hypersensitivity reactions (e.g., pruritus, rash, urticaria).

Serious Safety Concerns and Constraints

The regulatory label documents rare but serious adverse reactions including severe hepatic injury (liver damage), with some post-marketing cases resulting in liver failure. Acute pancreatitis and oxalate nephropathy (a kidney disorder) are also officially listed as rare concerns. The gastrointestinal effects are noted as being most pronounced at the start of treatment and are directly influenced by the fat content of the diet.

Thincal is formally contraindicated in patients with pre-existing conditions such as chronic malabsorption syndrome and cholestasis. A high-level safety consideration is the potential for reduced absorption of fat-soluble vitamins (A, D, E, K), and the medicine is not recommended for use during pregnancy or breast-feeding.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope (Official Regulatory Information)

Property	Regulatory Statement
Documented overdose presentations	Studies involving single high doses (up to 800 mg) and multi-day supra-therapeutic doses (up to 400 mg three times daily) have been conducted without significant adverse clinical findings. Reported events in overdose cases are consistently similar to those reported with the recommended dose, primarily involving gastrointestinal effects.
Physiological systems affected	The regulatory profile reflects a lack of acute systemic toxicity. Any potential systemic effects resulting from the lipase-inhibiting properties are documented as being rapidly reversible.
Immediate medical help required	Official labeling mandates that, in the event of a suspected overdose, individuals seek immediate medical attention or contact a Poison Control Center right away.
Monitoring and observation requirements	No specific antidote is described in the official documents. Following a suspected significant overdose, the regulatory recommendation is for the patient to be observed for 24 hours in a medical setting.

Regulatory Classification Summary

Severity classification: The overdose risk is characterized by a lack of acute significant systemic toxicity and the expected rapid reversibility of any systemic effects.

Official overdose statements:

Regulatory documents confirm the absence of significant adverse findings following exposure to supra-therapeutic doses.
Official guidance explicitly mandates that a patient must seek immediate medical attention or contact a poison control center.
The regulatory recommendation includes the need for the patient to be observed for 24 hours.

Connection to the overall overdose profile: The official documents establish that the Orlistat overdose profile is defined by minimal systemic involvement and a low risk of acute severe toxicity. This profile necessitates immediate medical consultation and prescribed 24-hour observation to assess non-systemic effects, aligning with the lack of a specific antidote and the expectation of rapid effect reversibility.

Therapeutic Uses of Thincal

Main Uses of Thincal

Thincal is a medication indicated for the long-term management of obesity and significant overweight. Its primary function is to assist in weight reduction and to help maintain weight loss when used in conjunction with a calorie-restricted diet.

The medication is typically prescribed for individuals who meet specific criteria regarding their Body Mass Index (BMI). These groups generally include:

Individuals with a BMI of 30 kg/m² or greater (clinically classified as obese).
Individuals with a BMI of 27 kg/m² or greater who also have associated risk factors, such as type 2 diabetes, high blood pressure, or high cholesterol.

Therapeutic Benefits

Weight Reduction and Maintenance

The primary benefit of Thincal is its ability to facilitate weight loss by preventing a portion of dietary fats from being absorbed by the body. By inhibiting the enzymes that break down fats in the digestive system, the medication ensures that these fats are eliminated rather than stored. This mechanism helps patients lose more weight than they might achieve through diet and exercise alone.

Beyond initial weight loss, the medication is effective in helping patients maintain their lower weight. This prevents the common cycle of weight regain that often follows calorie-restricted diets.

Impact on Metabolic Health Factors

While the primary focus is weight management, the reduction of body mass through this treatment can have positive effects on various metabolic markers. Patients may observe improvements in factors associated with weight-related conditions, including:

Blood Sugar Management: Weight loss achieved through treatment can improve insulin sensitivity and help stabilize blood glucose levels, particularly in patients with type 2 diabetes.
Lipid Profile: Reduction in body weight is often associated with a decrease in total cholesterol and LDL (low-density lipoprotein) levels.
Blood Pressure: Sustained weight loss can contribute to the better management of hypertension, reducing the overall strain on the cardiovascular system.

Eligibility and Restrictions for Use

Thincal is officially approved for use in adults who meet specific Body Mass Index (BMI) criteria. This includes patients with a BMI of 30 kg/m^2 or greater, or those with a BMI of 27 kg/m^2 alongside weight-related conditions like hypertension or diabetes. Prescription-strength use is also approved for adolescents 12 years of age and older.

The medicine is contraindicated—meaning it must not be used—in several populations. This includes patients with pre-existing conditions such as Chronic Malabsorption Syndrome or Cholestasis. Use is also strictly prohibited during pregnancy and breastfeeding. Absolute non-eligibility applies to patients who are concurrently taking the immunosuppressant Cyclosporine.

For other groups, use is restricted or limited. Safety and efficacy of the prescription product are not established in children under 12 years of age. Caution is required for patients at risk for renal impairment or with a history of kidney stones, with official labeling recommending the monitoring of renal function.

What should I know about interactions with other medicines?

Thincal’s (Orlistat) interaction profile is defined by its localized, non-systemic activity within the gastrointestinal tract, which results in reduced absorption of fat-soluble compounds and certain lipophilic medicines. Official regulatory documents structure the interaction risk based on this absorption mechanism.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class	Official Interaction Pattern/Outcome
Fat-soluble Vitamins (A, D, E, K)	Reduced gastrointestinal absorption and decreased systemic exposure, necessitating daily multivitamin supplementation.
Cyclosporine (Immunosuppressant)	Reduced plasma concentrations, which requires administration to be separated by 3 hours to mitigate the effect.
Levothyroxine (Thyroid Hormone)	Decreased absorption, requiring administration to be separated by 4 hours.
Anticoagulants (e.g., Warfarin)	Increased anticoagulant activity (altered INR/Prothrombin Time) due to reduced absorption of Vitamin K, requiring close monitoring.
Antiepileptic Drugs (AEDs)	Reduced absorption, potentially leading to lower plasma levels and loss of seizure control, necessitating monitoring of patients.
Antiretroviral Drugs	Reduced systemic exposure, with official warnings regarding the risk of losing virological control, requiring frequent monitoring of HIV viral load.
Antidiabetic Agents	Potential for hypoglycemia due to weight loss; blood glucose levels require monitoring.

Co-administration with a diet high in fat (over 30% of daily calories) is officially documented to increase the incidence of gastrointestinal effects. Interaction studies indicate no effect on the pharmacodynamics of alcohol.

Mechanism of Action

Thincal (Orlistat) operates via a non-systemic mechanism confined entirely to the lumen of the gastrointestinal tract, acting specifically on the process of fat digestion and absorption. The core mechanism involves a direct molecular interaction with key digestive enzymes: gastric lipase and pancreatic lipase. Orlistat forms a covalent bond with the active serine residue at the catalytic site of these lipases, which functionally inactivates the enzymes. This targeted inhibition is the initial step that prevents the breakdown of dietary fat molecules.

This functional inactivation triggers a mechanistic cascade where approximately 30% of ingested fat remains as large, undigested triglycerides. Because these molecules cannot be absorbed across the intestinal wall, they are excluded from the bloodstream. This physical exclusion of unhydrolyzed fat results directly in a reduction in the systemic uptake of fat-derived calories.

The drug's action is dependent on the presence of its substrate (dietary fat/triglycerides) in the meal. The non-systemic nature of the mechanism means it only acts on newly ingested fat within the gut, and it has no capability to break down or affect existing body fat stores.

Dosage and Administration Information

Thincal, which contains the active substance orlistat, is administered via the oral route as a 120 mg hard capsule. The medication's general use principle is defined by its precise timing relative to food intake. The standard adult dose is 120 mg taken three times a day (TID), with the maximum total daily dose not to exceed 360 mg.

A core administration rule is that the dose must be taken with each main meal containing fat or up to one hour following the meal; if a meal is missed or contains no fat, the dose should be omitted. This regimen is also applied to adolescents 12 years and older.

Administration of Thincal is strictly adjunctive, meaning it must be used alongside a nutritionally balanced, reduced-calorie diet where the total fat intake is distributed across the three main meals and does not constitute more than approximately 30% of the daily caloric intake.

Because the medication reduces the absorption of dietary fat, the protocol requires patients to take a multivitamin supplement containing fat-soluble vitamins (A, D, E, K). To prevent interference with absorption, this supplement should be administered at a different time, such as at bedtime, or at least two hours before or after the Thincal capsule. Long-term use is established as a possibility; however, continuation is typically conditional, such as discontinuing therapy if less than 5% of initial body weight has been lost after 12 weeks of treatment.

Recent Clinical Evidence

Evidence for Initial Weight Reduction

The research base for Thincal (Orlistat) largely consists of numerous Randomized Controlled Trials (RCTs) and subsequent meta-analyses, which are foundational to regulatory decisions. These trials were used in research exploring how body weight changes over time, particularly during the initial phase of management, typically spanning defined short-term periods. The participants were mostly adults classified as obese or overweight who were also following a mandatory reduced-calorie diet and lifestyle change program. In controlled trials, the weight change observed in participants receiving the medicine and diet/lifestyle support was compared to the weight change observed in those receiving placebo.

It is important to understand that the research highlights what is known—and what is still uncertain. Findings describe group patterns, not personal outcomes. The results apply only to the populations studied and generally report the average change observed.

️ Evidence for Sustained Weight Maintenance

Research has explored the use of Thincal to support long-term weight patterns and minimize the amount of weight change observed over time. These research scenarios involved large long-term RCTs that followed participants for extended periods, some up to four years. These extended studies monitored and compared the patterns of weight change during the maintenance phase between the group continuing to receive the medicine and the group switched to placebo.

Long-term effects are not fully established beyond the observation periods of the pivotal trials. A key limitation reported in the scientific literature is that follow-up durations were limited and participant dropouts (attrition) were observed in the groups studied over several years. This means that data for certain groups remain insufficient, making the outcomes in the very long term less certain.

Studies on Obesity-Related Health Factors

The same clinical trials that examined weight change also monitored outcomes related to obesity-related health risk factors. Researchers tracked biomarkers in the blood, such as lipid profiles and glycemic control indicators. Research examined differences measured during the study period between the study groups. Data show patterns where the incidence of progression to Type 2 Diabetes Mellitus was tracked in some populations observed over the longer term.

What remains uncertain is the independent contribution of the medicine to these risk factor changes, as the findings reflect changes that occurred concurrently with overall weight loss and lifestyle modifications.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Thincal (FAQ)

Q: Is Thincal available over the counter?

A: The active ingredient in Thincal is orlistat. This ingredient is described in official product information as being available in two forms: a higher strength that requires a prescription, and a lower strength (60 mg) formulation that is available for purchase without a prescription (over the counter).

Q: What happens if I miss a dose of Thincal?

A: If a dose is missed, official patient instructions advise that the dose should be skipped, and the patient should return to their regular dosing schedule. Patients are advised not to take a double dose to account for a missed one.

Q: How quickly does Thincal start working?

A: The functional effect of the medicine begins relatively quickly after the first dose. Official documents describe that an increase in the amount of undigested fat in the stools, which reflects the action of the medicine in the gut, can be observed as early as 24 to 48 hours after administration.

Q: How long does the effect of Thincal last after a dose?

A: The effect of the medicine in the gut is confined to the digestive tract. Regulatory information indicates that the fat content of stools typically returns to pre-treatment levels within 48 to 72 hours after stopping therapy.

Q: Does Thincal cause fatigue or drowsiness?

A: Fatigue (feeling tired or weak) is listed in some official documentation as an undesirable effect that patients may experience. However, official product information does not commonly report drowsiness as a side effect.

Q: Are the side effects of Thincal temporary or do they last the entire time taking the drug?

A: The most common side effects of this medicine are related to the digestive system, such as oily spotting and fecal urgency. Official information describes these effects as typically being most pronounced at the beginning of treatment and tending to lessen after some time.

Q: Does Thincal interact with herbal supplements?

A: Specific herbal supplements are not generally listed in the regulatory interaction tables. Official information indicates that it is important for a healthcare professional to be aware of all products being used, including vitamins and herbs, due to the potential for interference with the absorption of other substances.

Q: What happens if Thincal is taken with alcohol?

A: Interaction studies described in official product information have generally indicated that the medicine has no known effect on the absorption or breakdown of alcohol in the body. As with any medicine, it is helpful for patients to discuss use conditions with a healthcare professional.

Q: Is Thincal available as a generic medicine?

A: Yes, the active ingredient in Thincal is orlistat. This active ingredient is also available as a generic medicine, which is regulated by government agencies to be therapeutically equivalent to the brand-name product.

Q: What is the difference between brand-name Thincal and its generic version?

A: Brand-name Thincal and its generic equivalent, orlistat, contain the identical active ingredient. Regulatory standards require these products to be therapeutically equivalent, meaning they are expected to work in the same way. Any differences are typically limited to the product's inactive ingredients or presentation.

Q: Why do some people stop taking Thincal?

A: Official treatment protocols describe that therapy is typically discontinued if a patient has not lost at least 5% of their initial body weight after 12 weeks of treatment. This is a common condition for discontinuation.

Q: Is it normal to feel a change in appetite while using Thincal?

A: The medicine's primary effect is on fat digestion in the gut, and it does not directly act as an appetite suppressant. While the primary effect is not appetite suppression, some studies have examined its potential effects on factors related to feelings of fullness.

Q: Can Thincal be crushed or split if the pill is too large?

A: Official administration instructions for the capsule form advise that the medicine should be swallowed whole. There is no official information stating that the capsule may be crushed, split, or physically modified.

Q: What are the common misunderstandings people have about Thincal?

A: A frequent misunderstanding relates to how the medicine works. Official documents describe the mechanism as non-systemic, meaning its influence is localized to the gut to block fat absorption from food. It does not work by dissolving or burning existing fat stores in the body.

Q: Does Thincal have any restrictions on driving or operating machinery?

A: According to official product information documents, the medicine has no known influence on a person's ability to drive or safely operate machinery.

How should Thincal be stored and disposed of?

Storage and Disposal Requirements for Thincal (Orlistat)

Official regulatory documents define strict conditions for storing orlistat to maintain product quality and safety.

Storage Conditions

Thincal must be stored at Controlled Room Temperature, typically 20 C to 25 C. Storage temperatures must not exceed 25 C for blisters or 30 C for bottles. The medicine must be protected from excessive light and moisture.

Packaging and Safety

Capsules in blister packs must remain in the original outer carton. Bottles must be kept tightly closed to ensure protection from moisture. Thincal must always be stored out of the sight and reach of children.